Add like
Add dislike
Add to saved papers

Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution.

To date the British Salivary Gland Tumour Panel has accumulated 2569 salivary gland tumours. Of these, 2410 were primary epithelial salivary gland tumours and these formed the basis of the present study. The diagnosis of individual tumours was based on the World Health Organisation classification. Tumours were analysed according to histological type, site, age and sex. The principal site was the parotid and the combined minor (oropharyngeal) glands formed the second largest group. Pleomorphic adenomas formed the largest group of tumours in most sites, but were particularly common in the parotid. The frequency of malignant tumours increased with age after the third decade and was maximal in the eighth decade. Malignant tumours were more common in the submandibular and the minor glands than in the parotid. In the sublingual gland six out of seven tumours were malignant.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app